Levron is developing a novel autonomic integrated diagnostic and therapeutic minimally invasive device intended to be used with cardiac failure patients. The company's device integrates diagnosis and treatment, shifts fluids from the lung, and reduces cardiac workloads. The device provides adaptive treatment for NYHA stage 3 heart failure, eliminating lung congestion.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Levron Cardiovascular Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Nov 23, 2025
www.einpresswire.com
Levron Medical Exits Stealth to Establish New Category of Heart Failure Treatment Through CRPA Technology